Vertex Pharmaceuticals
VRTX
680 hedge funds and large institutions have $39.3B invested in Vertex Pharmaceuticals in 2018 Q1 according to their latest regulatory filings, with 96 funds opening new positions, 243 increasing their positions, 241 reducing their positions, and 55 closing their positions.
75% more first-time investments, than exits
New positions opened: 96 | Existing positions closed: 55
10% more funds holding in top 10
Funds holding in top 10: 10 → 11 (+1)
9% more capital invested
Capital invested by funds: $35.9B → $39.3B (+$3.39B)
6% more funds holding
Funds holding: 644 → 680 (+36)
1% more repeat investments, than reductions
Existing positions increased: 243 | Existing positions reduced: 241
0.24% more ownership
Funds ownership: 94.78% → 95.02% (+0.24%)
15% less call options, than puts
Call options by funds: $188M | Put options by funds: $220M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital World Investors
Los Angeles,
California
|
+$508M |
| 2 |
Massachusetts Financial Services
Boston,
Massachusetts
|
+$248M |
| 3 |
Jennison Associates
New York
|
+$202M |
| 4 |
VOYA Investment Management
Atlanta,
Georgia
|
+$168M |
| 5 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$151M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$231M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$214M |
| 3 |
State Street
Boston,
Massachusetts
|
-$154M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$153M |
| 5 |
Two Sigma Investments
New York
|
-$142M |
VRTX Hedge Fund Activity: Q1 2018 in Review
680 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Vertex Pharmaceuticals (VRTX) for Q1 2018, worth a combined $39.3B — up 9.4% from $35.9B a quarter earlier.
Buyers outnumbered sellers: 96 funds opened new VRTX positions and 55 closed out — a net gain of 41 holders — while 243 added to existing stakes and 241 trimmed.
The largest buyer was Capital World Investors, adding an estimated $508M. The largest seller was JP Morgan Chase, cutting an estimated $231M.
- 680 institutional investors held Vertex Pharmaceuticals (VRTX) as of Q1 2018, up from 644 in Q4 2017.
- Funds reported $39.3B of Vertex Pharmaceuticals stock for Q1 2018, up 9.4% quarter-over-quarter.
- 96 funds opened new Vertex Pharmaceuticals positions in Q1 2018 and 55 closed out, a net change of +41 holders.
- The largest Vertex Pharmaceuticals buyer in Q1 2018 was Capital World Investors, an estimated $508M added.
- The largest Vertex Pharmaceuticals seller in Q1 2018 was JP Morgan Chase, an estimated $231M sold.
Based on aggregated 13F filings for Q1 2018.